OGN

MERRILL LYNCH STRATEGIC RET. NOTES - OIL&NATURAL GAS 3/28/07

OGN

Overview Fund Activity

Delisted

OGN was delisted on the 22nd of March, 2007.

Back to rankings

Financial journalist opinion

Zacks Investment Research

Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know

Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.

Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know

Zacks Investment Research

Organon (OGN) Stock Declines While Market Improves: Some Information for Investors

Organon (OGN) concluded the recent trading session at $10.26, signifying a -1.06% move from its prior day's close.

Organon (OGN) Stock Declines While Market Improves: Some Information for Investors

Kuehn Law Encourages Investors of Organon & Co. to Contact Law Firm

NEW YORK , Sept. 9, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Organon & Co. (NYSE: OGN) breached their fiduciary duties to shareholders.

Kuehn Law Encourages Investors of Organon & Co. to Contact Law Firm

US Food and Drug Administration (FDA) Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

SHANGHAI & JERSEY CITY, N.J.--(BUSINESS WIRE)--FDA Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp).

US Food and Drug Administration (FDA) Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

Zacks Investment Research

Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.

Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It

NYSE: OGN Lawsuit Alert: Investors who lost money with Organon & Co. (NYSE: OGN) shares should contact the Shareholders Foundation

SAN DIEGO , Aug. 13, 2025 /PRNewswire/ -- The Shareholders Foundation, Inc. announced that a lawsuit was filed for certain investors in shares of Organon & Co. (NYSE: OGN). Investors who purchased shares of Organon & Co. (NYSE: OGN) prior to October 2024 and continue to hold any of those NYSE: OGN shares, also have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

NYSE: OGN Lawsuit Alert: Investors who lost money with Organon & Co. (NYSE: OGN) shares should contact the Shareholders Foundation

Organon: Valuation Discount Offset By Structural Headwinds

Organon shares are very cheap, but weak growth, high debt, and a lack of clear catalysts make them a value trap rather than a bargain. Revenue is stagnating as new products only offset legacy declines; cost-cutting helps margins, but can't reverse the downward trend in earnings. Valuation discounts already reflect worst-case scenarios; fair value is around $9 per share, leaving little upside unless growth drivers emerge.

Organon: Valuation Discount Offset By Structural Headwinds

Zacks Investment Research

Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know

Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know

Zacks Investment Research

OGN vs. HQY: Which Stock Is the Better Value Option?

Investors interested in Medical Services stocks are likely familiar with Organon (OGN) and HealthEquity (HQY). But which of these two stocks is more attractive to value investors?

OGN vs. HQY: Which Stock Is the Better Value Option?

Organon Q2 Earnings: It May Be Time To Desert This Sinking Ship (Downgrade)

Organon & Co.'s shrinking revenues, heavy debt, and slashed dividend make it an unattractive investment despite its low valuation metrics. The Established Brands division is in decline, and new products like Emgality and VTAMA are not offsetting losses from older drugs. Women's Health and Biosimilars show some growth, but not enough to reverse the overall negative trend or justify optimism.

Organon Q2 Earnings: It May Be Time To Desert This Sinking Ship (Downgrade)

See News Rankings

Charts implemented using Lightweight Charts™